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ABSTRACT

UNCOVERING CONSTRAINTS ON ORGANOID MORPHOLOGIES
Lauren E. Beck
Arjun Raj

Organoids recapitulate complex 3D organ structures and represent a unique opportunity to
probe the principles of self-organization. While we can alter an organoid’s morphology by manipulating the culture conditions, the morphology of an organoid often resembles that of its original
organ, suggesting that organoid morphologies are governed by a set of tissue-specific constraints.
Here, we establish a framework to identify constraints on an organoid’s morphological features by
quantifying them from microscopy images of organoids exposed to a range of perturbations. We
apply this framework to Madin-Darby Canine Kidney cysts and show that they obey a number of
constraints taking the form of scaling relationships or caps on certain parameters. For example, we
found that the number, but not size, of cells increases with increasing cyst size. We also find that
these constraints vary with cyst age and can be altered by varying the culture conditions. This quantitative framework for identifying constraints on organoid morphologies may inform future efforts to
engineer organoids.
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Chapter 1

Introduction
1.1

Organoid systems are expected to transform many fields of
biomedical research but still suffer from low reproducibility

For the past century, scientists have sought to expand our understanding of human biology through
the use of cell culture and animal models. Both cell culture and animal models have seen near ubiquitous use and have enabled countless discoveries. Unfortunately, both systems have limitations.
Traditional 2D cell culture techniques, while relatively cheap and easy to maintain, cannot recapitulate the 3D nature of the cells’ endogenous environment. Animal studies provide a resource for
studying cells and tissues in their endogenous contexts, but are expensive, time-consuming, and
do not always reflect human physiology. To overcome these limitations scientists have turned to
organoids, 3D organ-like structures that can be grown in vitro from single or small groups of human
cells. Organoids have the potential to transform biomedical research, since thousands of human
organ-like tissues can now be easily cultured in vitro.
The use of organoids, or at least the term organoid, may seem to have exploded in the past
decade (Clevers, 2016; Simian & Bissell, 2017). In fact, some of the 3D culture systems in use

1

today have been around since the 1980s (Chambard et al., 1981; Hall et al., 1982) and the culture of tissue fragments dates as far back as 1906 (Harrison, 1906). That a long history of 3D
culture techniques predates the deluge of organoid systems discovered in the 2000s and 2010s
has caused some debate in the field. Specifically, what constitutes an organoid? The more lenient
definitions consider organoids to be any 3D structure that can survive explantation or that can be
cultured in vitro through the process of self-organization (Shamir & Ewald, 2014; Simian & Bissell,
2017). Other definitions go further, insisting that organoids must arise specifically from stem cells
or at least partially recapitulate the differentiated cell types, morphology, or function of the original
organ (Clevers, 2016; Fatehullah et al., 2016; Kim et al., 2020; Lancaster & Knoblich, 2014). Here,
we will use a more lenient definition of the term organoid, one that refers to any 3D structure of
cells that arises through self-organization.
Regardless of the precise definition, it is clear biologists now have a rich set of organoid systems at their disposal. Organoids have been developed from healthy and diseased tissues, from
individual cells or cell clusters, from adult or induced pluripotent stem cells, and in bioreactors or
embedded in matrices. The list of organs culturable as organoids is now nearly as long as the list
of organs in the human body. Though this list is far from complete, organoids have been derived
from organs of the following organ systems:
• cardiovascular: heart (Giacomelli et al., 2017; Tiburcy et al., 2017), blood vessel (Wimmer
et al., 2019)
• lymphatic: germinal center (Purwada et al., 2015), thymus (Tajima et al., 2019)
• digestive: stomach (Barker et al., 2010), intestine (Sato et al., 2009), liver (Hu et al., 2018;
Peng et al., 2018), pancreas (Huch et al., 2013)
• endocrine: thyroid (Saito et al., 2018), pituitary (Cox et al., 2019)
• nervous: brain (Kadoshima et al., 2013; Lancaster et al., 2013), retina (Eiraku et al., 2011),
inner ear (Koehler et al., 2013), salivary gland (Tanaka et al., 2018)
2

• reproductive: testes (Baert et al., 2017), fallopian tubes (Kessler et al., 2015), prostate (Drost
et al., 2016)
• respiratory: lung (Dye et al., 2015), trachea (Rock et al., 2009)
• muscular: skeletal (Maffioletti et al., 2018)
• skeletal: bone (Akiva et al., 2020)
As the list of organoid systems continues to grow, so too do their uses. Organoids have been
used to study stem cells niches (Murrow et al., 2017), culture previously unculturable cell types
(Grün et al., 2015; Hu et al., 2018; Peng et al., 2018), and model the early stages of human development (Simunovic & Brivanlou, 2017). There is even some hope that organoids could be used
therapeutically as transplants. For example, multiple groups have successfully restored glucose
homeostasis by transplanting pancreatic islet-like organoids into diabetic mice (Lebreton et al.,
2019; Yoshihara et al., 2020). If all these applications were not enough, many hope that organoids
will be transformative for personalized medicine and for the study of 3D- or human-specific diseases.
Organoids have proven particularly exciting for personalized medicine. Numerous groups have
established organoid biobanks (Li et al., 2020), large collections of organoid lines derived from
patient biopsies. Two separate biobanks of organoids derived from colorectal cancer have been
used to map genetic mutations to drug response (Fujii et al., 2016; van de Wetering et al., 2015)).
Others have taken a further step towards personalized drug testing by showing that patient-derived
organoids can be used to predict up to 80% of the original tumor’s response to chemotherapy or
radiation (Ganesh et al., 2019; Ooft et al., 2019; Vlachogiannis et al., 2018; Yao et al., 2020).
Organoid biobanks have proved useful outside cancer as well. One group has established a
biobank of intestinal organoids derived from patients with cystic fibrosis (Dekkers et al., 2016).
Researchers showed that a patient’s drug response could be predicted from the drug response of
their organoid, an important milestone disease where it has proven difficult to predict which drugs
3

will prove effective against a patient’s specific set of disease-causing mutations (Sosnay et al.,
2013).
Perhaps the most transformative application of organoid technologies is studying diseases that
cannot be recapitulated in 2D culture systems or animal models. This is particularly true for virology.
Brain organoids were used to provide some of the first evidence that prenatal Zika virus exposure
could lead to microcephaly (Qian et al., 2016). Noroviruses, which are highly contagious and one
of the most common causes of gastroenteritis (de Graaf et al., 2016), could not be cultured in
vitro until it was successfully demonstrated in intestinal organoids (Ettayebi et al., 2016). Recently,
researchers have used kidney and capillary organoids to understand the tissue tropism of SARSCoV-2 (Monteil et al., 2020), the virus responsible for the ongoing COVID-19 pandemic.
Given that organoids provide researchers with a unique tool for studying 3D, human-specific
biology, it is clear that organoids are here to stay. Nonetheless, organoids are still a relatively new
tool compared to traditional 2D cell culture and animal models. What hurdles must be overcome to
realize the full potential of organoid systems?
Many organoid systems are plagued by low reproducibility in that organoids cultured under
seemingly similar conditions can have quite variable sizes, shapes, and cellular compositions. In
this way, organoids’ remarkable self-organization abilities are both an advantage and a disadvantage. The researcher has little control over the process and minimal ability to influence the phenotype of the final organoid. Many have speculated that more control over the process would help
combat the low reproducibility plaguing many organoid systems (Garreta et al., 2020; Huch et al.,
2017; Kim et al., 2020). Indeed, recent approaches to engineer various aspects of the culture process have yielded more uniform organoids (Gjorevski et al., 2016; Grabinger et al., 2014; Lancaster
et al., 2016; Qian et al., 2016; Völkner et al., 2016).
However, it is important to distinguish the problem of experimental robustness from organoids’
phenotypic heterogeneity. In many cases these problems may go hand-in-hand. Another possibility
is that organoid heterogeneity is, while inconvenient because it may mean that more organoids
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need to be analyzed, an advantage. This may be particularly true in the case of organoids derived
from patient biopsies, where variability in organoids may reflect the heterogeneity of the original
tumor. Nonetheless, it is clear that we understand relatively little about the phenomena that give
rise to poor reproducibility in organoid systems. In this thesis, we will describe an approach to
map the rules that govern which morphologies an organoid system can adopt. Our hope is that
quantitatively describing organoid morphologies to a new level of detail will enable future work to
both work with and understand the origins of organoid phenotypic heterogeneity.

1.2

The need for algorithms to systematically quantify 3D cultures

One potential reason that there are few quantitative analyses of organoid morphologies is it has
proven difficult to automate the analysis of microscopy images of large three-dimensional structures. Indeed, our ability to automatically analyze microscopy images of such large structures has
not kept pace with the innovations that enabled the images to be taken in the first place (Huisken
et al., 2004; Keller et al., 2008; Ueda et al., 2020). Traditional methods for automating image analysis seek to quantify images by searching for known shapes or textures. Though many of these
techniques exist, they have not always generalized well to data sets other than the one for which
they were built (Piccinini et al., 2020). More recent approaches have made significant advances
using deep learning methods (Berg et al., 2019; Haberl et al., 2018; Hollandi et al., 2020; McQuin
et al., 2018; Ronneberger et al., 2015; Schmidt et al., 2018; Stringer et al., 2020; Tokuoka et al.,
2020). While deep learning-based techniques are already generalizing to novel data sets better,
they can also be more easily tuned to improve performance without having to completely re-train
the network (Chen et al., 2019; Zhang et al., 2020).
Another exciting approach to image analysis is the use of crowdsourcing (Bafti et al., 2021;
Hughes et al., 2018; Sullivan et al., 2018). Here, researchers are able to format their image analysis
5

problems into simple tasks that can be completed by non-researchers with minimal training. Nonresearchers complete these tasks for payment or for free as part of an online. In this format,
extremely large datasets can be analyzed almost overnight since hundreds or thousands of people
can contribute in parallel. However, it can be challenging to ensure the accuracy of submissions
and time-consuming to build and maintain the platform and user base.
Aside from the accuracy of the algorithms or the workers, a couple of factors make the widespread
use of existing algorithms difficult. The first is that potential users have to invest a non-trivial amount
of time to get the algorithm running on their computers before they can even evaluate how useful
the algorithm will be. Users often must install source code and dependent software packages (instructions for which can be highly system-dependent or altogether lacking) and reformat their data
to the format required by that algorithm before they can test the algorithm’s performance on a single
image. Thankfully, some recent publications have also made websites that allow potential users to
quickly test the algorithm on their data (Stringer et al., 2020). Another challenge for the field is the
lack of software that allows users to manually touch up the results of an algorithm. Though this
solution can be tedious, it’s worth weighing the time needed to manually fix a portion of the data
against the unknown amount of time it may take just to demo existing approaches whose accuracy
can be difficult to predict a priori.
Previous quantitative studies of organoid morphologies have been limited to a small set of twodimensional features, such as organoid area and nuclear intensity, that fail to fully capture many
characteristic aspects of the organoid’s shape (Gracz et al., 2015; Kassis et al., 2019). A major
challenge is that quantifying morphological features such as the number of cells, cell shapes, etc.,
often requires microscopy images be annotated to outline each individual cell or nucleus. While
algorithms for automatic segmentation for images of large three-dimensional structures are improving, in many instances, segmentation must still be done at least partially manually to ensure
sufficient accuracy. Such issues are compounded in organoids with many cell types and complex
three-dimensional structures that are difficult to quantitatively align and compare to each other.
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Simpler “model” organoid systems might serve as a proving ground to test concepts about morphospaces.

1.3

Our approach: identifying constraints that govern organoid
morphologies

It is clear that organoids can form intricate biological structures, and these structures have an
overall morphology that always resembles the associated organ. Yet, at the same time, there is
often enormous variability between individual organoids (Garreta et al., 2020; Kim et al., 2020; Koo
et al., 2019; Phipson et al., 2019; Volpato et al., 2018), and changing the organoid culture protocol
can similarly lead to large changes (Gjorevski et al., 2016; Sidhaye & Knoblich, 2020; Yin et al.,
2014). Thus, the question remains as to what rules govern organoid morphologies. Which aspects
of organoid morphologies are free to vary and which are immutable? Are there constraints, perhaps
in the form of scaling relationships between various organoid morphological features, that give rise
to the stereotyped nature of organoid appearances? Categorizing organoid features in this way
may help reveal the design principles underlying organoid development.
One way to formalize the concept of constraints is via the dimensionality of morphospace, which
is the set of morphologies an organism or model system can have. An organoids morphospace can
be considered a set of high dimensional axes, where each axis represents one particular morphological feature (e.g. organoid volume, number of cells, etc). If one were to measure enough features
of an organoid’s morphology across a large number of organoids, it could be that a large number of
these features would strongly covary and thus could be explained by a single variable. For example,
if size and number of nuclei were to be strongly correlated, then the dimensionality would effectively
be 1 instead of 2, and the relationship between these variables would constitute a constraint on
organoid morphology. On the other hand, if variables show a lack of correlation, then that would
suggest independent axes of variability, indicating an additional degree of freedom in organoid mor7

phospace. Examples of such dimension reduction have been demonstrated in both C. elegans and
Snapdragon flowers, four dimensions capture over 90% of the variance in morphologies (Cui et al.,
2010; Stephens et al., 2008). However, such analyses have not been performed in organoids yet.
Recent work has quantitatively described brain organoid morphologies (Albanese et al., 2020) and
uncovered genetic interactions governing intestinal organoid morphologies (Lukonin et al., 2020),
but the constraints on organoid morphologies have not been characterized.
How might we characterize the constraints on organoid morphologies? Our approach was to
use variation in organoid morphology—both naturally occurring and variation induced by external
stimuli—to sample the organoid morphospace. As a proof of concept, we developed this approach
in spherical cysts grown from Madin-Darby Canine Kidney (MDCK) cells. We then quantified morphological features (cyst size, number of cells, eccentricity, etc) and the relationships between them
(how does the number of cells scale with cyst size), thus revealing the constraints on MDCK cyst
morphologies. To overcome the challenge of systematically quantifying morphological features,
we combined algorithms for generating candidate annotations with software that allowed for quick
manual correction. We found that MDCK cyst morphologies all fell along a small set of dimensions.
These dimensions encoded a number of constraints; for instance, larger cysts had increased number but not size of constituent cells. We also found that some of these constraints on MDCK cyst
morphologies vary with age and can be perturbed through drugs and growth factors. Our results
demonstrate a general strategy for determining the ways in which organoid morphologies are either
constrained or free to vary.
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Chapter 2

Results
2.1

MDCK cyst morphologies span a limited number of dimensions

To quantify constraints on cyst morphologies, we designed an experimental and analytical workflow for culturing cysts, performing 3D imaging, annotating structures of interest, and measuring
morphological features (Figure 2.1). We chose to apply this approach to MDCK cysts because of
their relative simplicity and because they are amenable to high magnification 3D imaging. MDCK
cells are an immortalized epithelial line that grow in adherent culture on 2D substrates, but form
hollow 3D cysts when cultured in 3D matrices such as collagen or Matrigel (Figure 2.2). A MDCK
cyst grows from a single cell and is composed of an outer layer of polarized cells surrounding one
to many lumens. The combination of their simplicity with the existence of a number of structural
features to quantify make MDCK cysts an ideal system for establishing a framework for quantifying
constraints on organoid morphologies.
(We evaluated other organoid systems, such as the gut organoids, for our analysis, but found
that the complexity of their morphologies presented a much larger challenge. For instance, gut
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organoids have complex bud structures that one would need to align to each other for quantitative
comparison. The comparative simplicity of MDCK cysts that are at least nominally spherical made
our analysis feasible as a proof of principle, with MDCK cysts serving as a model for more complex
organoids.)
In order to quantify 3D measurements of morphological features for hundreds of MDCK cysts,
we established a pipeline for semi-automatically annotating cyst structures (nuclei, lumens, and cyst
boundary). To identify the lumen and cyst boundaries, we developed a custom analysis pipeline that
generated candidate annotations and accepted manual corrections to the annotations as needed
(Figures 2.3, 2.4, and 2.5). We used cellpose to identify the boundaries of each nucleus and a
custom analysis pipeline to manually correct the 3D annotations (Figures 2.6 and 2.7). Due to
depth of field limitations, in many cases we could not image the full depth of the cyst. We thus
made sure to image at least the bottom half of the cyst, from which we computationally determined
the middle point of each cyst and measured features on only the bottom half of each cyst to ensure
a fair comparison between all cysts. We then measured morphological features of size, shape, and
number on the nuclei, lumen, and cyst annotations anticipating that these may be the features that
vary amongst cysts (Appendix B). We performed a variety of comparisons between morphological
features in order to verify that our measurements were consistent with basic geometric constraints.
For example, because the cysts always appeared spherical, we confirmed that the cyst volume
scaled with the cube of the cyst radius (Figures 2.8). We also confirmed that the total lumen and
total nuclear volume was always less than that of the cyst volume, and we visually inspected cysts
with high and low feature metrics to confirm that the quantified differences reflected differences in
the images (Figures 2.9, 2.10, 2.11, 2.12, and 2.13).
We then wanted to find relationships between features that could potentially reflect biological
constraints. For example, did the number of cells scale with the size of the cyst? Or, did larger
cysts have the same number of cells as smaller cysts, but with larger component cells? We used
the number of nuclei as a proxy for the number of cells and found that larger cysts had proportionally

10

more nuclei (Figure 2.14). Because cells peripheral to the lumen(s) had different morphology than
those internal to the lumens, we wondered whether their number scaled differently with cyst volume.
We found that the number of peripheral nuclei scaled sublinearly with cyst volume. Surprisingly, the
number of internal cells scaled superlinearly with cyst volume, thus ensuring that the total number of
cells scaled linearly with cyst volume. Given that the number of cells scaled with the cyst volume, we
predicted that cell size should be independent of cyst size. We found that despite increases in cyst
volume the peripheral cell height and width are constant at 12 µm and 15 µm, respectively (Figures
2.15 and 2.16). Together, we called this set of constraints the constant-cell-density constraint.
We also wondered how lumens, both in number and size, scaled with increasing cyst size. For
example, if a cyst is larger must it also have larger lumens? One alternative is that there is maximum
lumen size, and larger cysts then have multiple lumens of the same size as smaller cysts. We found
that the total lumen volume increased with increasing cyst volume, but that this could be achieved
through one large lumen or many smaller lumens (Figures 2.17, 2.18, and 2.19). However, we did
notice that there was seemingly a maximum number of lumens per cyst that increased linearly with
cyst volume. We called this constraint the “lumen number cap”, and its existence suggests that
there may be a minimum lumen size (Figure 2.20).
Given that MDCK cysts obey a number of constraints, we then wondered whether these constraints are coupled. In other words, might there be a single dimension (or a few dimensions),
each of which may comprise several correlated features, along which all MDCK cyst morphologies
fall (Figure 2.21)? To identify dimensions in the space of MDCK cyst morphologies we performed
principal component analysis on the set of 77 cysts and their 66 morphological features. In order
to apply principal component analysis to our data, we needed to supply a single value for each
feature for each cyst. For all features describing nuclei we used both the mean and standard deviation across all nuclei within the cyst, e.g. mean nuclear volume and standard deviation of nuclear
volume. For features describing lumens we used the mean across all lumens in the cyst, e.g. mean
lumen volume. We did not include other higher order statistics like standard deviation because
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it was impossible to do so for the many cysts that had only one lumen. We found that the first
three principal components respectively explain 30%, 19%, and 10% of the variation in MDCK cyst
morphologies (Figure 2.22). We then wondered whether the principal components reflected any
of the constraints we had previously identified. We found that the first principal component represented lumen size and inversely nuclear size, reflecting the fact that as lumens get larger, nuclei
get smaller (Figures 2.23, 2.24, 2.25, and 2.26). The second principal component represents cyst
size and number of nuclei, reflecting that increased cyst size was associated with increased number of nuclei, a relationship we previously identified as the constant-cell-density constraint. The
third principal component represented the trade-off between lumen size and the number of lumens,
reflecting that, for a given cyst size, in order to have more lumens, the individual lumens must be
smaller (rather than there is a maximum lumen size which is independent of the number of lumens).
The third principal component also represented a trade-off between nuclear size and the density of
nuclei, reflecting that, for a given cyst size, in order to have more nuclei the nuclei must be smaller
(2.27 and 2.28). (Consistent with PC1, we also found that nuclear size anti-correlated with lumen
size.) Beyond those three principal components, the remaining components accounted for less
variation than components calculated from randomized data, suggesting that those PCs likely do
not reflect substantial variation in the data. Thus, despite quantifying a large number of features,
MDCK cyst morphologies can thus be represented by a limited number of dimensions.

12

culture MDCK
cysts for
7 - 11 days

media
Matrigel
MDCK cyst
phalloidin
DAPI

perform 3D
imaging

20 μm
cyst
phalloidin

lumens
phalloidin

annotate
structures
in 2D

nuclei
DAPI

get 3D
annotations
cyst radius: 37.8 μm
lumen eccentricity:
0.34
number of nuclei:
61
etc.
...

44.7 μm
0.46
181
...

54.1 μm
0.59
356
...

quantify
morphology

Figure 2.1: Schematic of pipeline to quantify MDCK cyst morphological features. Briefly, we culture
cysts for a variable number of days, perform 3D imaging of nuclei and cell boundaries for at least
half of the cyst, annotate the boundaries of the cyst and each nucleus and lumen, and measure
morphological features on the 3D annotations.
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Figure 2.2: We maintain MDCK cells in two-dimensional culture. When the cells are sufficiently
confluent, we dissociate the cells into a single cell suspension. Then, we combine cells to liquid
Matrigel and plate the cell-Matrigel mixture onto a cell culture chamber already coated with pure
Matrigel. After the Matrigel has polymerized, we add media and culture the cysts for 3-17 days.
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Figure 2.3: Our user interface for viewing and correcting 2D annotations.
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Figure 2.4: A. Example images of MDCK cysts. B. Example candidate annotations for the cyst
boundary. C. Example annotations for the cyst boundary after correction.
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Figure 2.5: A. Example images of MDCK cysts. B. Example candidate annotations for the lumen
boundary. C. Example annotations for the lumen boundary after correction.
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Figure 2.6: Our user interface for viewing and correcting 3D nuclear annotations.
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Figure 2.7: Example nuclear annotations, color-coded by which 3D object they belong to (A) before
manual correction and (B) after manual correction.
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Figure 2.8: Cyst volume versus cyst radius for 7-11 day old MDCK cysts. Reference line indicates
the relationship between radius and volume of half a sphere.
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Figure 2.9: Total lumen volume versus cyst volume for 7-11 day old MDCK cysts. Reference line
indicates y = x.
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Figure 2.10: Total nuclear volume versus cyst volume for 7-11 day old MDCK cysts. Reference line
indicates y = x.
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Figure 2.11: Cyst radius for 7-11 day old MDCK cysts with example images.
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Figure 2.12: Number of nuclei for 7-11 day old MDCK cysts with example images.
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Figure 2.13: Mean lumen eccentricity for 7-11 day old MDCK cysts with example images.
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Figure 2.14: A. Example MDCK cyst with peripheral nuclei annotated with a red x and internal
nuclei annotated with an orange x. B. Number of nuclei versus cyst volume for 7-11 day old MDCK
cysts. C. Number of peripheral nuclei versus cyst volume for 7-11 day old MDCK cysts. D. Number
of internal nuclei versus cyst volume for 7-11 day old MDCK cysts.
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Figure 2.15: Mean peripheral cell height versus cyst radius for 7-11 day old MDCK cysts.
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Figure 2.16: Mean peripheral cell width versus cyst radius for 7-11 day old MDCK cysts.
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Figure 2.17: Total lumen volume versus cyst volume for 7-11 day old MDCK cysts.
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Figure 2.18: Number of lumens versus cyst volume for 7-11 day old MDCK cysts.
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Figure 2.19: Mean lumen radius versus cyst radius for 7-11 day old MDCK cysts.
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Figure 2.20: Histogram (with a bin width of 1 um) of mean lumen radius for MDCK cysts cultured
for 7-11 days.
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Figure 2.21: Schematic of MDCK cyst morphologies that are captured by 1 dimension or 2 dimensions.
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Figure 2.22: Percentage of morphological variance explained by the first 15 principal components
for 7-11 day old MDCK cysts. The red line indicates how much variance is explained when the data
is randomized before principal component analysis.
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Figure 2.23: Loadings of each feature of the first three principal components for 7-11 day old MDCK
cysts. Each feature is color-coded by what structure (cyst, lumen, nucleus, or cell) it describes.
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Figure 2.24: Principal component scores versus morphological features (that have high loadings
for that principal component) for 7-11 day old MDCK cysts.
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Figure 2.25: Principal component score 1 versus principal component score 2 and 3 for 7-11 day
old MDCK cysts. Each pair of example images were chosen because they have high and low score
for one principal component, and similar scores for the other two principal components.
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Figure 2.26: Mean nuclear volume versus mean lumen volume for 7-11 day old MDCK cysts with
example images.
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Figure 2.27: Number of lumens versus mean lumen volume for 7-11 day old MDCK cysts with
example images.
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Figure 2.28: Density of nuclei versus mean nuclear volume for 7-11 day old MDCK cysts with
example images.
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2.2

Constraints on MDCK cyst morphologies vary with age

MDCK cysts grow continuously over the course of weeks, from a single cell into large cysts. To determine whether or not cyst age affects the constraints on MDCK cyst morphologies, we compared
the quantitative relationship between various features for cysts of different ages. We partitioned our
data based on cyst age, ranging from 3-17 days of growth. Using the same imaging and feature
quantification described above, we saw that, as expected, old cysts were larger in volume on average (Figure 2.29 and 2.30). We also noticed that, for a given age, there was a spread in cyst sizes.
This variation in size enabled us to compare constraints in cyst size across different age categories
(Figure 2.31). We used cysts cultured for 9 days as a reference point for younger and older cysts
to evaluate how constraints on MDCK cyst morphologies changed with cyst age.
We first wondered if the constant-cell-density constraint varied for cysts of different ages (Figure
2.32). We found that cysts grown for 7-11 days obeyed the constant-cell-density constraint on the
number of nuclei and cyst volume. However, cysts cultured for 3-5 or 13-17 days did not obey this
constraint—they had fewer nuclei per cyst volume. Interestingly, while older cysts are generally
bigger, for older cysts that are small for their age, the number of nuclei for a given volume was
similar to that of middle aged cysts. This size-dependent change suggests that the decrease in the
cell density in older cysts may be more dependent on these older cysts having reached a certain
threshold volume rather than the age of the cyst per se. We looked at the age dependence of the
cell size component of the constant-cell-density constraint (Figure 2.33). We found that younger
cysts did not obey the same constraint as cysts culture for 9 days, instead they had larger cells per
cyst volume.
Having established that at least one constraint on MDCK cyst morphologies is age-dependent,
we wondered whether other constraints were similarly affected by age. We looked at the age
dependence of the lumen-number-cap constraint (Figure 2.34). We found that both younger and
older cysts obeyed different constraints than cysts cultured for 9 days: cysts cultured for 3 days
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had a higher maximum number of lumens per cyst volume, and cysts cultured for 13-17 days had
a lower maximum number of lumens per cyst volume. The decrease in the number of lumens as
cysts age beyond 9 days suggests that multiple lumens in a cyst are either merging or disappearing
as cysts grow older. In summary, both the constant-cell-density and lumen-number-cap constraints
were not fixed throughout the cyst lifetime but rather varied with age.
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Figure 2.29: Images of MDCK cysts cultured for 3-17 days. Each scale bar represents 20 µm.
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Figure 2.30: Quantification of cyst radius for MDCK cysts cultured for 3-17 days.
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Figure 2.31: Schematic of a constraint that does or does not vary with MDCK cyst age.
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Figure 2.32: Number of nuclei versus cyst volume for MDCK cysts cultured for 3-17 days. Each
age is represented by one color, and MDCK cysts cultured for 9 days are repeated on each graph
for reference. The line represents the line of best fit and the shaded area represents the 95%
confidence interval. Example images of MDCK cysts with approximately the same number of nuclei
but different volumes. Each scale bar represents 20 µm.
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Figure 2.33: Mean cell volume versus cyst volume for MDCK cysts cultured for 3-17 days. Each
age is represented by one color, and MDCK cysts cultured for 9 days are repeated on each graph
for reference. The line represents the line of best fit and the shaded area represents the 95%
confidence interval. Example images of MDCK cysts with approximately the same volume but
different mean cell volumes. Each scale bar represents 20 µm.
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Figure 2.34: Number of lumens versus cyst volume for MDCK cysts cultured for 3-17 days. Each
age is represented by one color, and MDCK cysts cultured for 9 days are repeated on each graph
for reference. The line represents the line of best fit and the shaded area represents the 95% confidence interval. Example images of MDCK cysts with approximately the same number of lumens
but different cyst volumes. Each scale bar represents 20 µm.
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2.3

Drug and environmental perturbations can change MDCK
cyst constraint parameters but do not break them

Having found constraints on MDCK cyst morphologies, we wondered whether these constraints
applied to cysts whose morphology we perturbed using exogenous agents. For example, if we
perturb the cysts with a drug which makes the cysts larger, will the same constant-cell-density
constraint still apply? If not, there are two ways that the constraint could be disobeyed. One is
that the perturbed cysts could follow the same constraint but with different parameters, for example,
by changing the slope of the relationship between cell number and cyst volume. Alternatively,
a perturbation could qualitatively remove a constraint and decouple, for example, the number of
nuclei and cyst volume. Either of these possibilities would suggest that the constraints on MDCK
cyst morphologies are context-specific.
There are few references to drugs which modify the morphology of MDCK cysts in the literature.
Thus, to identify drugs that change MDCK cyst morphologies we designed a high-throughput drug
screen of small molecule drugs from Selleck Chemicals Bioactive Compound library. This library
contains 2,000 small molecule drugs including kinase and epigenetic inhibitors as well as ion
channel, metabolic, and cancer compounds. To conduct the screen, we plated MDCK cells in 384well plates, added 1 µM of each drug, and allowed the cells to grow into cysts for seven days,
at which point the cysts were fixed and imaged. We then quantified the area of each cyst and
the average across cysts for each perturbation. We found that, while most drugs did not appear
to change the area of the cyst relative to controls, there were many drugs which made the cysts
smaller or larger (Figure 2.35). We considered “hits” for larger cysts to be the drugs that were
on both the list of the top 100 drugs as ranked by fold change and the list of the top 100 drugs
as ranked by z-score, a total of 78 drugs. We found 80 “hits” for smaller cysts using the same
approach. We found that hits that resulted in smaller cysts were enriched for drugs in the kinase,
epigenetic, and cancer categories, while hits for larger cysts were enriched for kinases, cancer,
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and G protein-coupled receptor categories (Figure 2.36). To gauge how many of our hits may have
arisen by chance, we screened a portion (1/7th) of the drug library again. We found that there
was a correlation (r=0.63) between the fold change in cyst area from the screen and this targeted
replication, suggesting that the majority of our hits were not random (Figure 2.37). The screen hits
represented potential candidates for perturbing MDCK cyst morphologies and then asking whether
perturbed MDCK cysts obey the same constraints as unperturbed cysts.
We further grouped hits for smaller and larger cysts according to their targets (Table 2.1 and
2.2). We selected four drugs from our list of hits from the screen that increased cyst size from
groups targeting mammalian target of rapamycin, aurora kinase, phosphodiesterase, and serotonin.
Similarly, we selected three drugs that made cysts smaller from groups targeting epidermal growth
factor receptor, histone deacetylases, and exportin-1. We additionally used idelalisib, an inhibitor
of the delta form of phosphoinositide 3-kinase shown to affect MDCK cyst polarity, and oratinib, an
inhibitor of platelet-derived growth factor receptor. We plated MDCK cells to form cysts, immediately
added these drugs at a range of concentrations, and then grew the cysts for 9 days (Table 2.3).
Additionally, we tested a non-drug perturbation (cell seeding density) by culturing MDCK cysts
with a higher initial cell density (the concentration of the cells when seeding the cysts). We then
fixed, stained, and imaged the perturbed cysts as described above, after which we measured the
same set of morphological features (Figure 2.38 and 2.39). We found that the screen hits that we
expected to make cysts smaller did indeed lead to smaller cysts, but none of the ones predicted to
make them larger did so. We found that increased seeding density had no effect on the size of the
cysts.
We then wondered whether perturbed cysts obeyed the same constant-cell-density and lumennumber-cap constraints as unperturbed cysts. We found that, with the exception of two drugs
(selinexor and sumatriptan succinate), perturbed cysts obeyed the same constant-cell-density constraint as unperturbed cysts (Figure 2.40 and 2.41). Cysts perturbed with sumatriptan succinate (a
serotonin receptor inhibitor) had more nuclei per given cyst volume than any age of unperturbed
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cysts, while cysts perturbed with selinexor (an exportin-1 inhibitor) had larger nuclei per given cyst
volume. Notably, the relationship between cell number, size, and cyst volume is still constrained
for cysts perturbed with either of these drugs, but the parameters of the constraint (specifically the
slope) are different from unperturbed cysts.
We then wondered how a perturbation which does change a constraint influences other constraints—if cysts perturbed with drug X do not obey the constant-cell-density constraint, must they
also not obey the lumen-number-cap constraint? We found that cysts perturbed with givinostat (a
histone deacetylase inhibitor), idelalisib (a phosphoinositide 3-kinase delta isoform inhibitor), sumatriptan succinate, and Aurora A Inhibitor I had more lumens in a given cyst volume than unperturbed
cysts of any age (Figure 2.42). Thus, cysts perturbed with these drugs do not obey the same
lumen-number-cap constraint of unperturbed cysts, instead they obey a constraint with a larger
slope. Further, some perturbations (givinostat, idelalisib, and Aurora A Inhibitor I), which changed
the lumen-number-cap constraint, did not change the constant-cell-density constraint. That some
perturbations change one constraint without changing the other suggests that the set of morphologies available to MDCK cysts is richer than unperturbed cysts would suggest.
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Figure 2.35: Fold change in cyst area versus each drug from the screen. Annotated drugs are
those used in further experiments.
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Figure 2.36: Proportion of drugs categories for (A) all 2,087 drugs used in the screen, (B) the 80
drugs found to decrease cyst area, or (C) the 78 drugs found to increase cyst area.
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Figure 2.37: Fold change in MDCK cyst area for a drug in the targeted screen versus in the original
screen.
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Table 2.1: We identified 78 hits from the drug screen for making
larger MDCK cysts. The drugs are grouped by their targets. The
catalog number refers to the SelleckChem catalog. The drugs
marked with a X were used in perturbation experiments.

Drug

Catalog Number

PI3K, AKT, and mTOR Group

X

A66

S2636

CZC24832

S7018

NU7026

S2893

PI-103

S1038

PP242

S2218

YM201636

S1219

CCT128930

S2635

MK-2206 2HCl

S1078

DNA Damage Group
Caffeic Acid Phenethyl Ester

S7414

VE-822

S7102

Capecitabine

S1156

Costunolide

S1319

Aurora Kinase Group
X

Aurora A Inhibitor I

S1451

CCT137690

S2744

CYC116

S1171

Bcr-Abl Group
DCC-2036 (Rebastinib)

S2634

55

Table 2.1 (continued from previous page)
Drug

Catalog Number

GZD824

S7194

Nilotinib (AMN-107)

S1033

CDK Group
KT7519

S1524

MK-8776 (SCH 900776)

S2735

Palbociclib (PD-0332991) HCl

S1116

RAF, MEK, and ERK Group
AZ 628

S2746

GW5074

S2872

SB590885

S2220

Adrenergic Receptor Group
Clorprenaline HCl

S4135

Xylazine HCl

S2516

Histamine Group
Cimetidine

S1845

Ketotifen Fumarate

S2024

JAK Group
CYT387

S2219

Ruxolitinib (INCB018424)

S1378

PDE Group
X

PF-2545920

S2687

Pentoxifylline

S4345

Serotonin Group
X

Sumatriptan Succinate

S1432
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Table 2.1 (continued from previous page)
Drug

Catalog Number

Trazodone HCl

S2582

Src Group
Bosutinib (SKI-606)

S1014

PP1

S7060

Drugs with Unique Targets
Glipizide

S1715

Amfenac Sodium Monohydrate

S4149

Ferulic Acid

S2300

Formononetin

S2299

Meprednisone

S1689

Mometasone furoate

S1987

Penicillin G Sodium

S4160

Rifaximin

S1790

Thiamet G

S7213

Triamcinolone Acetonide

S1628

VGX-1027

S7515

(-)-Blebbistatin

S7099

Cyclopamine

S1146

DMXAA (Vadimezan)

S1537

Dexamethasone acetate

S3124

Fasudil (HA-1077) HCl

S1573

Fingolimod (FTY720) HCl

S5002

GDC-0152

S7010

GSK3787

S8025
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Table 2.1 (continued from previous page)
Drug

Catalog Number

GW788388

S2750

Griseofulvin

S4071

Indirubin

S2386

Isradipine

S1662

Mifepristone

S2606

Mubritinib (TAK 165)

S2216

AG-1024

S1234

PHA-665752

S1070

PX-478 2HCl

S7612

SB216763

S1075

SKLB1002

S7258

Sitaxentan sodium

S3034

Sotrastaurin

S2791

Thioguanine

S1774

VX-745

S1458

Thiamine HCl (Vitamin B1)

S3211

Disodium Cromoglycate

S1911

Drugs with Many Targets
Cabozantinib (XL184, BMS-907351)

S1119

Dovitinib (TKI-258, CHIR-258)

S1018

Golvatinib (E7050)

S2859

NVP-BHG712

S2202

Ponatinib (AP24534)

S1490

TG101209

S2692
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Table 2.2: We identified 80 hits from the drug screen for making
smaller MDCK cysts. The drugs are grouped by their targets. The
catalog number refers to the SelleckChem catalog. The drugs
marked with a X were used in perturbation experiments.

Drug

Catalog Number

EGFR and HER2 Group

X

AEE788 (NVP-AEE788)

S1486

AZD8931 (Sapitinib)

S2192

Afatinib (BIBW2992)

S1011

Canertinib (CI-1033)

S1019

Dacomitinib (PF299804, PF299)

S2727

Gefitinib (ZD1839)

S1025

Lapatinib (GW-572016) Ditosylate

S1028

Neratinib (HKI-272)

S2150

Pelitinib (EKB-569)

S1392

HDAC Group

X

AR-42

S2244

Belinostat (PXD101)

S1085

Entinostat (MS-275)

S1053

Givinostat (ITF2357)

S2170

M344

S2779

Mocetinostat (MGCD0103)

S1122

PCI-24781 (Abexinostat)

S1090

Pracinostat (SB939)

S1515

Scriptaid

S8043
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Table 2.2 (continued from previous page)
Drug

Catalog Number

PI3K, AKT, and mTOR Group
AZD8055

S1555

Everolimus (RAD001)

S1120

GDC-0980 (RG7422)

S2696

WYE-125132 (WYE-132)

S2661

GSK2126458 (GSK458)

S2658

INK 128 (MLN0128)

S2811

Torin 2

S2817

Aurora Kinase Group
AMG-900

S2719

Barasertib (AZD1152-HQPA)

S1147

GSK1070916

S2740

Hesperadin

S1529

PF-03814735

S2725

SNS-314 Mesylate

S1154

Topoisomerase Group
Idarubicin HCl

S1228

SN-38

S4908

Topotecan HCl

S1231

Camptothecin

S1288

Mitoxantrone HCl

S2485

Teniposide

S1787

RAF, MEK, and ERK Group
AZD8330

S2134
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Table 2.2 (continued from previous page)
Drug

Catalog Number

PD0325901

S1036

Pimasertib (AS-703026)

S1475

TAK-733

S2617

Trametinib (GSK1120212)

S2673

CRM1 Group

X

KPT-185

S7125

KPT-276

S7251

KPT-330

S7252

Epigenetic Reader Domain Group
(+)-JQ1

S7110

CPI-203

S7304

GSK1324726A (I-BET726)

S7620

Microtubule Associated Group
Vinblastine

S1248

Nocodazole

S2775

Fosbretabulin Disodium

S7204

CDK Group
Flavopiridol HCl

S2679

PHA-793887

S1487

DHFR Group
Pralatrexate

S1497

Methotrexate

S1210

Drugs with Unique Targets
LB42708

S7467
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Table 2.2 (continued from previous page)
Drug

Catalog Number

MPI-0479605

S7488

NSC697923

S7142

ONX-0914 (PR-957)

S7172

OTX015

S7360

Olanzapine

S2493

Oligomycin A

S1478

RG108

S2821

Raltitrexed

S1192

Roflumilast

S2131

Volasertib (BI 6727)

S2235

Tipifarnib

S1453

Erastin

S7242

A-769662

S2697

BIIB021

S1175

BMN 673

S7048

Cephalomannine

S2408

Evodiamine

S2382

Flubendazole

S1837

Y-320

S7516

Guanethidine Sulfate

S4328

Nanchangmycin

S1450

Acetanilide

S2538

Drugs with Many Targets
AT9283

S1134
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Table 2.2 (continued from previous page)
Drug

Catalog Number

Danusertib (PHA-739358)

S1107
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Table 2.3: We used 9 drugs at multiple concentrations to perturb MDCK cyst morphologies.
Drug

Concentrations

selinexor

0.1, 0.3 µM

lapatinib

40, 130, 400 nM

givinostat

0.1 µM

PI-103

0.1, 0.3 µM

idelalisib

3, 10, 30 µM

mardepodect

0.1, 1.0 µM

sumatriptan succinate

0.1, 0.3, 1.0 µM

Aurora A Inhibitor I

0.1, 0.3, 1.0 µM

orantinib

0.5, 1.6, 5.0 µM
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seeding density: low
drug: none
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DMSOv
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selinexor
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none
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Figure 2.38: Images of MDCK cysts cultured for 9 days in different drugs and different cell seeding
densities. Each scale bar represents 20 µm.
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Figure 2.39: Quantification of cyst radius for MDCK cysts exposed to various drug perturbations.
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Figure 2.40: Number of nuclei versus cyst volume for MDCK cysts exposed to drug perturbations.
The line represents the line of best fit and the shaded area represents the 95% confidence interval.
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Figure 2.41: Mean cell volume versus cyst volume for MDCK cysts exposed to drug perturbations.
The line represents the line of best fit and the shaded area represents the 95% confidence interval.
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Figure 2.42: Number of lumens versus cyst volume for MDCK cysts exposed to drug perturbations.
The line represents the line of best fit and the shaded area represents the 95% confidence interval.
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2.4

Constraints of perturbed MDCK cysts do not add or average when multiple perturbations are applied

Exposing MDCK cysts to hepatocyte growth factor (HGF) in collagen gels induces cells to send
out spindly protrusions (Montesano, Schaller, and Orci 1991; Montesano et al. 1991). These protrusions form the groundwork for a chain of cells to proliferate and ultimately form tubules. We
wondered how such a perturbation might change the constraints on cyst morphologies we identified, given that it leads to known, qualitative changes in cyst morphology. We added 5 ng/mL or
20 ng/mL HGF to MDCK cysts as they grew for nine days (Figure 2.43). We used our imaging and
feature quantification approach to characterize the constraints on cysts exposed to HGF. We asked
whether our measurements of cyst shape captured the morphology of spindles in HGF-perturbed
cysts. We found that one of the primary differences between unperturbed and HGF-perturbed
cysts was cyst solidity, a measure of convexity (cysts with more involutions or protrusions have
lower solidity than circular or elliptical cysts) (Figure 2.44). Mean cyst solidity decreased from 0.93
for unperturbed cysts to 0.75 for HGF-perturbed cysts. We also found that cysts exposed to HGF
were larger, on average, than unperturbed cysts (Figure 2.45).
Given the qualitative difference in morphology of HGF-perturbed cysts, we wondered if HGFperturbed cysts obeyed the constraints obeyed by unperturbed MDCK cysts. We found that HGFperturbed cysts did not obey both aspects of the constant-cell-density constraint: while cysts perturbed with HGF had the same number of cells per cyst volume, the cells were larger than those of
unperturbed cysts of any age (Figure 2.46 and 2.47). How do HGF-perturbed cysts have the same
number of cells per cyst volume, but larger cells than unperturbed cysts? One possibility was that
HGF-perturbed cysts have a smaller proportion of their volume taken up by lumens and a larger
proportion of the volume occupied by cells. Interestingly, HGF-perturbed cysts do obey the lumennumber-cap constraint, suggesting that what lumens HGF-perturbed cysts have are smaller in size
but similar in number (Figure 2.48). The smaller proportion of volume taken up by the lumens
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could result from cells being taller or adopting a different configuration. We found that the cells
often formed multi-cell layers, which allows for larger cells to occupy the same organoid volume
while maintaining the same total number of cells per volume. It also suggests that the strict proportionality between cell number and organoid volume is maintained despite disruptions to cellular
configurations and hence cell number may not be controlled by morphology per se.
Given that HGF qualitatively changed some features of MDCK cysts, we wondered what the
morphological effects would be upon combining HGF with the previously used perturbations that
engendered more quantitative changes. For example, would a perturbation that produces spindly
cysts (HGF) and a perturbation that produces smaller cysts yield small, spindly cysts? We perturbed MDCK cysts for nine days with either HGF alone or HGF in combination with lapatinib,
orantinib, or with a high starting cell density and HGF (Figure 2.49). We found that cysts exposed
to HGF and lapatinib or oratinib had lower solidity, but cysts perturbed with HGF and high cell density did not (Figure 2.50). We found that cysts exposed to HGF, alone or in combination, were also
larger, on average, than control cysts (Figure 2.51). Taken together, the morphological changes
induced by HGF and another perturbation suggest that the effects of individual perturbations do
not necessarily combine additively when administered simultaneously.
We then wondered how the constraints of cysts perturbed with HGF changed when the cysts
were exposed to a second drug. One possibility is that doubly-perturbed cysts obeyed a set of
constraints that somehow averaged the constraints obeyed by singly-perturbed cysts. Another
possibility is that doubly-perturbed cysts obeyed the same set of constraints as only one of the perturbations, suggesting that some drugs may be able to override the effects of others. We first asked
if cysts perturbed with HGF and another drug obeyed the same constant-cell-density constraint as
cysts perturbed with only HGF (Figure 2.52 and 2.53). Cysts perturbed with two perturbations,
HGF and lapatinib, oratinib, or high starting cell density, did obey the same constant-cell-density
constraint as unperturbed cysts, even though cysts perturbed with HGF alone did not. This difference between the constant-cell-density constraint obeyed by doubly-perturbed cysts and singly-

71

perturbed cysts suggests that some perturbations (specifically oratinib, lapatinib, and high starting
cell density) are able to cancel out the effects of others (HGF). We also found that only cysts perturbed with both HGF and another perturbation did not obey the same lumen-number-cap constraint
as unperturbed cysts, even though cysts perturbed with just one of these perturbations did obey
the constraint (Figure 2.54). Cysts perturbed with HGF and lapatinib, oratinib, or high cell density
had more lumens for a given cyst volume than unperturbed cyst. In combination, differences between the constraints obeyed by double-perturbed cysts and single-perturbed cysts suggests that
the effects of any given perturbation do not appear to simply add together, but rather can combine
in unanticipated ways.
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Figure 2.43: Images of MDCK cysts cultured for 9 days in HGF. Each scale bar represents 20 µm.
White arrows indicate spindles.
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Figure 2.44: Quantification of cyst solidity for MDCK cysts exposed to HGF.
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Figure 2.45: Quantification of cyst radius for MDCK cysts exposed to HGF.
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Figure 2.46: Number of nuclei versus cyst volume for MDCK cysts exposed to HGF. The line represents the line of best fit and the shaded area represents the 95% confidence interval.
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Figure 2.47: Mean cell volume versus cyst volume for MDCK cysts exposed to HGF. The line
represents the line of best fit and the shaded area represents the 95% confidence interval.
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Figure 2.48: Number of lumens versus cyst volume for MDCK cysts exposed to HGF. The line
represents the line of best fit and the shaded area represents the 95% confidence interval.
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Figure 2.49: Images of MDCK cysts cultured for 9 days with multiple perturbations. Each scale bar
represents 20 µm. A. The two perturbations are HGF and lapatinib. B. The two perturbations are
HGF and oratinib. C. The two perturbations are HGF and high seeding density.
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Figure 2.50: Quantification of cyst solidity for MDCK cysts exposed to multiple perturbations. A.
The two perturbations are HGF and lapatinib. B. The two perturbations are HGF and oratinib. C.
The two perturbations are HGF and high seeding density.
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Figure 2.51: Quantification of cyst radius for MDCK cysts exposed to multiple perturbations. A. The
two perturbations are HGF and lapatinib. B. The two perturbations are HGF and oratinib. C. The
two perturbations are HGF and high seeding density.
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Figure 2.52: Number of nuclei versus cyst volume for MDCK cysts exposed to multiple perturbations. The line represents the line of best fit and the shaded area represents the 95% confidence
interval. A. The two perturbations are HGF and lapatinib. B. The two perturbations are HGF and
oratinib. C. The two perturbations are HGF and high seeding density.
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Figure 2.53: Mean cell volume versus cyst volume for MDCK cysts exposed to multiple perturbations. The line represents the line of best fit and the shaded area represents the 95% confidence
interval. A. The two perturbations are HGF and lapatinib. B. The two perturbations are HGF and
oratinib. C. The two perturbations are HGF and high seeding density.
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Figure 2.54: Number of lumens versus cyst volume for MDCK cysts exposed to multiple perturbations. The line represents the line of best fit and the shaded area represents the 95% confidence
interval. A. The two perturbations are HGF and lapatinib. B. The two perturbations are HGF and
oratinib. C. The two perturbations are HGF and high seeding density.
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Chapter 3

Discussion
3.1

Summary of Results

We established a framework to quantify the constraints on organoid morphologies. Our approach
was to use the morphological variation in the organoids, both naturally occurring and that induced
by drug, to identify a number of scaling relationships between various morphological features. In
order to systematically measure organoid morphological features for hundreds of organoids we built
a pipeline to convert microscopy images of organoids into 3D computational reconstructions of the
organoids and their structures. We then used these 3D annotations to systematically measure a
number of organoid morphological features.
As proof-of-concept, we applied this framework to MDCK cysts. We found that the majority of
morphological variation in MDCK cysts could be explained by only three dimensions. We identified
two constraints governing MDCK cyst morphologies. One, which we named the constant-celldensity constraint, governs the linear scaling between the number of cells and the volume of the
cyst. The other, which we named the lumen-number-cap constraint, governs the relationship between the maximum number of lumens and the volume of the cyst. We found that the exact nature
of these constraints, specifically their slopes, varies with the age of the cyst. We also found that
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some drug perturbations can similarly alter the slope of these constraints, but that no perturbation
broke a constraint. We also found that the constraints of MDCK cysts that have been perturbed
with multiple drugs do not reflect simple addition or averaging of the constraints of MDCK cysts
perturbed with only one drug.

3.2
3.2.1

Future Directions
What mechanisms might underlie constraints on organoid morphologies?

It remains unclear what underpins the constraints on MDCK cyst (or, more generally, organoid)
morphologies. One could imagine any number of potential mechanisms that underpin constraints.
One example mechanism may be conventional biochemical signaling, whether that be the complex
milieu of networks within cells or the signaling that occurs between cells. Another question is
whether constraints are governed solely by the genetics of the system. Or, perhaps the constraints
of a system reflect an interplay between genetics and the environment and the exact parameters of
an organoid’s constraints will vary depending on the environment in which it grows.
Furthermore, does the existence of a constraint suggest there is a single phenomenon governing that relationship? Or, does the existence of a constraint, and its persistence despite perturbation, suggest that many phenomena interacting with each other are what gives rise to such
a robust constraint? While many potential mechanisms may be compatible with our experimental data, further perturbations will be required to exclude certain classes of models and establish
causality.
We also found that while some perturbations altered organoids within the confines of the constraint, others altered the parameters of the constraints. It may also be possible, with sufficient
perturbation, to destroy a constraint, for example to completely decouple cyst volume from the
number of cells.
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However, it is also possible that the complexity of the underlying molecular pathways is too great
and multi-faceted to ever fully relate to these constraints in an easily understood manner. Nevertheless, knowledge of constraints and others like them may constitute an effective mapping between
the possible inputs (growth environment, drugs, age, genetic background) and outputs (morphologies) of an organoid system. One could imagine that such a map might enable researchers to build
an organoid with a set of desired characteristics without having to understand the precise molecular
mechanisms governing the process.

3.2.2

How can we alleviate the image analysis bottleneck?

The main challenge we faced in the work described here was extracting MDCK cyst annotations
from microscopy images. Using deep learning for image analysis has led to a great number of
advances for the field and it is likely that in the years to come deep learning will all but solve the
problem of turning images into numbers. However, some key hurdles remain. The first is that
most of the applications of deep learning to biological image annotation focus on identifying the
boundaries of nuclei or cells. While fast and accurate annotation of these structures enables the
field to answer many otherwise unanswerable questions, they represent only a small fraction of the
structures that biologists may want to quantify in their images. Therefore, it is likely that the path
towards fully automated image analysis involves deep learning algorithms that are not just highly
accurate, but also highly adaptable to using for related, but different, applications.
Another challenge for the future of fully automated image analysis is how accurate the annotations need to be to answer the question of interest. In our work, we assumed that we would need
highly accurate annotations to reveal subtle constraints on MDCK cyst morphologies. An obvious
solution may be to build or look for the algorithm that achieves complete accuracy. However, the
time spent building or searching for that algorithm ought to be considered just as much as the time
the algorithm will save the user. Specifically, if the goal is to obtain the necessary annotations as
quickly as possible, how long will it take to manually improve the algorithm’s results as opposed to
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tweaking the algorithm until the results are better? This question is exceedingly difficult to answer
because it can be extremely challenging to predict if changes to an algorithm will improve its accuracy. A more fruitful path for those looking to use, but not build, image analysis algorithms is to
consider what level of accuracy they will need to successfully answer their question. Having a clear
answer to this question may help researchers more quickly tackle their image analysis problems in
an area where it is far too easy to imagine that the perfect algorithm must exist.

3.2.3

How might this framework be applied to other organoid systems?

We focused on MDCK cysts for our proof of concept because of their simplicity, both morphologically and in terms of the number of cell types involved (in this case, just one cell type). Many
organoids of interest have several cell types that interact in various ways, presumably to maintain
function. It will be interesting in the future to apply this framework to such multi-cell-type organoids
to see what constraints are obeyed by the much richer feature sets associated with multi-cell-type
interactions.
One difficulty in applying this framework to other organoid systems is that their large sizes may
make imaging and annotating structures of interest even more challenging. However, that need not
be the case. An assumption in our work was that we would need complete 3D annotations of the
organoid to best capture the morphological variation of the MDCK cysts. This assumption meant
that we had to annotate the organoid structures of each of the twenty to sixty slices in the 3D image.
However, it’s possible that annotating organoid structures on just one of those slices would have
been sufficient to capture the morphological variation between organoids. An example workflow
might be to computationally identify the slice containing the middle of the organoid. Then, the user
or their algorithm would annotate the structures of interest only for that slice, drastically reducing the
time required to obtain accurate annotations for the organoid. Though this approach may capture
less of the morphological variation between organoids, it may be possible to offset those losses by
similarly drastically increasing the number of organoids analyzed. Such a framework could serve
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to drastically decrease the time required to image and annotate one organoid, making it much
easier to apply this approach to other larger organoid systems. As proof-of-concept, one could
retroactively apply this approach to our data, which might inform exactly how much information
would be lost by focusing on 2D annotations and features, and how many more organoids would
need to be analyzed to make up for this loss of information.
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Appendix A

Methods
A.1

Experiments to Quantify Normal and Perturbed MDCK Cysts’
Morphological Features

A.1.1

Culturing MDCK Cells

We maintained Madin-Darby Canine Kidney-II cells (MilliporeSigma, 00062107-1VL) in 2D by culturing them on 10 cm cell culture-coated dishes (Corning, 353003) in a 37 ◦ C, 5% CO2 incubator.
The cells grew in MEM media (MediaTech, MT10-010-CM) supplemented with 10% Fetal Bovine
Serum (Fisher, 16000044) and 1X penicillin and streptomycin (Invitrogen, 15140122).
We passaged the cells whenever they reached approximately 90% confluence. To passage the
cells we first washed the dish once with 1X DPBS (Gibco, 14190136). Then, we added 1 mL of
0.25% Trypsin-EDTA (Gibco, 25200056) and returned the plate to the incubator for 10-15 minutes,
or until all cells had detached from the plate as visible through a bench top microscope. We then
added 9 mL of media to the dish to inactivate the trypsin. We then pipetted the media-trypsin
mixture up and down over the dish three times to ensure all cells detached from the plate. The
suspension was then transferred to a 15 mL conical tube and centrifuged at 1000 rpm at room

90

temperature for 2 minutes. We then aspirated the supernatant and suspended the pellet in 500 µL
to 1 mL of media. One-tenth to one-twentieth of the cells were plated in a new dish with 10 mL of
fresh media.

A.1.2

Culturing MDCK Cysts

We passaged a plate of MDCK cells 1 - 3 days before we wanted to make MDCK cysts so that the
cells would be at 30-70% confluence the day we wanted to make MDCK cysts. A few hours before
we wanted to make MDCK cysts we thawed a 500-1000 µL aliquot of Matrigel (Corning, 354234)
on ice.
To make MDCK cysts we first dissociated the cells from the plate using the same method as
when we passaged cells. Once the pelleted cells had been suspended in 500 µL to 1 mL media, we
quantified the cell concentration using a BioRad TC20 Automated Cell Counter. We then pipetted
the ice-cold thawed Matrigel up and down five times to ensure it was well mixed. Then, we added
cells to the Matrigel at a concentration of 25,000 cells/mL and pipetted up and down five times to
ensure the cells were well mixed. We left the cell-Matrigel mixture on ice while we coated the middle
of the well(s) of a Nunc Lab-Tek 8-well Chambered Coverglass (Fisher, 12-565-470) with 5 µL of
pure Matrigel. Then, we plated 25 µL of the cell-Matrigel mixture on top of the coating. We then
plated the chamber in the incubator for 30 minutes to polymerize the Matrigel. Finally, we added
200 µL of media to each well and returned the plate to the incubator. We cultured MDCK cysts for
3-17 days with media replaced every other day.
For perturbations we cultured MDCK cysts using the above technique with the following exceptions. For drug perturbations we cultured MDCK cysts in media containing drug throughout their
entire growth (Supp. Table 2). For the high starting cell density perturbation we plated MDCK cysts
from a cell-Matrigel suspension containing 100,000 cells/mL.
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A.1.3

Imaging MDCK Cysts

A.1.3.1

Fixing and Staining

We fixed and stained MDCK cysts at room temperature with two washes with PBS (Ambion,
AM9624) between each step. We used a pipette to do all liquid handling to avoid losing any of
the Matrigel from vacuum aspiration.
First, we removed the culture media and fixed the MDCK cysts by adding 200 µL of 1.85%
formaldehyde (MilliporeSigma, F1635-500ML) in PBS to each well. We fixed the MDCK cysts for
30 minutes. Then, we quenched the MDCK cysts by adding 200 µL of 50 mM NH4 Cl (Fisher, A661500) in PBS to each well. We quenched the MDCK cysts for 30 minutes. Then, we permeabilized
the MDCK cysts by adding 200 µL of Triton X-100 (MilliporeSigma, T8787-100mL) in PBS to each
well. We permeabilized the MDCK cysts overnight. Then, we blocked the cysts by adding 200 µL
of 5% Bovine Serum Albumin (MilliporeSigma, A7906-100G) in PBS to each well. We blocked the
MDCK cysts for 1 hour. Finally, we stained the MDCK cysts by adding 200 µL of stain solution,
PBS with a 1:15 dilution of 488-phalloidin (Invitrogen, A12379) and a 1:30 dilution of DAPI (Fisher,
D3571), to each well. We stained the MDCK cysts for at least 6 hours before we imaged them in
stain solution.

A.1.3.2

Microscopy

We imaged the MDCK cysts on a Zeiss Laser Scanning 710 Confocal Microscope using a 40X
objective (Zeiss, water immersion, 1.1 NA, long working distance, LD C-Apochromat), 405 nm
diode laser (Zeiss), and 488 nm argon-ion laser (LASOS). We imaged each cyst from the bottom to
a depth clearly beyond the middle point of the cyst. We did not image cysts that were too far from
the glass to image that deeply.
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A.1.4

Quantifying MDCK Cyst Morphological Features

We developed a custom MATLAB pipeline to measure MDCK cyst morphological features from
microscopy images. Briefly, the pipeline allows the user to annotate the boundaries of the whole
cyst and each of its lumens and nuclei in 3D. Then, the pipeline uses these 3D annotations to
quantify size and shape morphological features such as number of nuclei, cyst eccentricity, etc.
The pipeline is available for download at https://github.com/arjunrajlaboratory/organoids2 and
requires additional code available at https://github.com/arjunrajlaboratory/rajlabimagetools.

A.1.4.1

Annotations MDCK Cyst Structures in Images

We obtained complete 3D annotations for the cyst, each lumen, and each nucleus. Our general
approach was to use an algorithm to guess the 2D annotation of the structure on each image slice
and then use a different algorithm to connect the 2D annotations in 3D.
To guess the 2D cyst annotations on each image slice we set an empty corner of the image as
the starting boundary and expanded that boundary outward until the intensity of those pixels was
above a user-defined threshold. We then manually reviewed these 2D boundaries and corrected
them as needed (Supp. Fig. B). Once these 2D boundaries were finalized they were combined into
one object to form a single 3D boundary for each MDCK cyst.
We applied the same approach to guess the 2D lumen boundaries, except we identified the
starting point as the largest object after the slice had been processed with a Laplacian of Gaussian
edge detector. We obtained 3D lumen boundaries by computationally identifying which boundaries
touched one another when stacked in 3D.
To obtain 2D annotations of the nuclear boundaries in 2D we used cellpose. We found that these
annotations did not need any manual correction. We also sliced the image stack orthogonally from
its original slicing, such that moving between slices moves left-right across the cyst, rather than updown. We again used cellpose to annotate the nuclei on these orthogonal slices. We then used the
orthogonal 2D annotations to guess which original 2D annotations were connected to one another.
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We then manually reviewed these 3D connections and corrected them as needed (Supp. Fig. C).

A.1.4.2

Measuring Morphological Features from Annotations

Once we had 3D annotations for the cyst, lumens, and nuclei, we wrote custom analyses to measure morphological features of size, shape, and number for each cyst (Supp. Table 1). For cysts
with multiple lumens, we took the mean across all lumens. For cysts with multiple nuclei, we took
both the mean and the standard deviation across all nuclei.

A.1.5

Analysis

A.1.5.1

Principal Component Analysis

We first standardized the units of our features. We took the cube root of all volume features, the
square root of all surface area features, and the inverse of the number of lumens. Then, we z-score
normalized each feature. Finally, we ran principal component analysis in R using the prcomp function (https://www.rdocumentation.org/packages/stats/versions/3.6.2/topics/prcomp) from the stats
package.
To estimate how much variance we could expect to be explained due to chance, we also ran
principal component analysis on randomized data. To randomize the data we shuffled the contents
of each column in a matrix where each row represented the data from a single cyst and each
column represented a feature.

A.1.5.2

Linear Models

We fit linear models to pairs of morphological features in R using the geom smooth function (https:
//ggplot2.tidyverse.org/reference/geom smooth.html) from the ggplot2 package.
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A.2
A.2.1

Screen for Drugs that Change MDCK Cyst Size
Establishing MDCK Cells with Nuclear and Cell Membrane Markers

We established MDCK cells with stable integration of GFP nuclear and mCherry cell membrane
markers. The day before we planned to transfect the cells we plated them so that the cells would
be approximately 80% confluent at the time of transfection. We also culture the cells in media
without penicillin and streptomycin.
The following day, we used Lipofectamine 2000 (Invitrogen, 11668019) to transfect the cells with
H2B-GFP plasmid (https://www.addgene.org/11680/) according to Lipofectamine’s recommended
protocol. Two days after transfection we replaced the media with media containing penicillin, streptoymycin, and G418 (Mediatech, MT30-234-CR). We changed the media every other day. One
week after transfection we single cell bottlenecked the cells. We then followed the same approach
to transfect the cells with mem-mCherry plasmid (https://www.addgene.org/55779/). We maintained
the cells using the same method as described above, except with the addition of G418 in the media.

A.2.2

Culturing MDCK Cysts

To plate MDCK cysts for the screen we thawed Matrigel and dissociated 2D MDCK cells as described above. We added cells to the thawed, ice-cold Matrigel at a concentration of 35,000
cells/mL. We then used a Matrix WellMate to plate the cell-Matrigel mixture into 384-well plates.
Then, we centrifuged the plates at 300 rpm for 1 minute to ensure the Matrigel-cell suspension fell
to the bottom of the well. We then placed the plates in the incubator for 30 minutes to polymerize
the Matrigel. We used a Perkin Elmer Janus Modular Dispensing Tool to add 20 µL of media with
20 mM HEPES and drug to each well. Finally, we returned the plates to the incubator and cultured
the MDCK cysts for 7 days without any media changes.
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A.2.3

Imaging MDCK Cysts

A.2.3.1

Fixing and Staining

We fixed the cysts by adding 20 µL of 8% formaldehyde in PBS to each well, which combined with
the media in the well to a concentration of 4% formaldehyde. We fixed the MDCK cysts for 30
minuets at room temperature. Then, we washed the plates with 1X PBS. Finally, we added µL of
stain solution (1:2500 Hoescht in PBS). We incubated the MDCK cysts in stain solution overnight
before imaging the next day.

A.2.3.2

Microscopy

We used a Molecular Device’s ImageXpress Micro XLS Widefield High-Content Analysis System
to image each plate using a 10X objective. We took 4 images per well, which together covered the
entire well. The height of each image was determined by the autofocus software.

A.2.4

Quantifying MDCK Cyst Size

We quantified the effect of each drug on cyst size using custom MATLAB scripts. First, we combined
the three image channels, Hoescht, GFP, and mCherry. Then, we applied a Gaussian filter and
binarized the image using Otsu’s method. We then obtained the boundary of cysts by obtaining
the boundary of all objects in the binarized image that were bigger than 50 pixels and smaller than
1500 pixels. We calculated the area of each cyst using MATLAB’s regionprops function.
We then calculated the average fold change in cyst area for each drug by dividing the average
cyst area for the drug by the average cyst area for all control cysts from the same plate. We similarly
calculate the z-score for each drug.
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A.2.5

Analysis

A.2.5.1

Hit Identification

To identify hits from the screen we used MATLAB to make two lists, one that ranked the drugs in
order of average fold change and another that ranked the drugs in order of average z-score. We
considered the 78 drugs in the top 100 of both lists to be hits for making larger MDCK cysts. We
considered the 80 drugs in the bottom 100 of both lists to be hits for making smaller MDCK cysts.

A.3

Data and Code Availability

All data and code used for these analyses can be found at https://www.dropbox.com/sh/u2tqi7w235b63v6/
AADyq-LfaE2HS97lLfYCPBP4a?dl=0. We made all the graphs in R and formatted all the images
with MATLAB. Final figures were composed in Illustrator. We used a selection of color-blind friendly
colors from https://personal.sron.nl/∼pault/ for the figures.
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Appendix B

Morphological Features
B.1

Volume

Units:
µm3
Quantities Measured:
• cyst volume
• mean lumen volume
• mean nuclear volume
• standard deviation nuclear volume
Approach:
1. Calculate the number of voxels inside the object.
2. Multiply by the voxel volume.
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B.2

Cell Volume

Units:
µm3
Quantities Measured:
• mean cell volume
Approach:
1. Subtract the volume of all lumens from the cyst volume.
2. Divide by the number of nuclei.

B.3

Fraction of Cyst Volume

Units:
unitless
Quantities Measured:
• lumen fraction of cyst volume
• nuclear fraction of cyst volume
Approach:
1. Sum the volume of all lumens/nuclei.
2. Divide by the cyst volume.

B.4

Surface Area

Units:
99

µm2
Quantities Measured:
• cyst surface area
• mean lumen surface area
• mean nuclear surface area
• standard deviation nuclear surface area
Approach:
1. Use MATLAB’s regionprops function to calculate the perimeter of the object on each image
slice.
2. Sum the perimeters over all image slices.
3. Multiply by the size of the voxel in XY and the size of the voxel in Z.

B.5

XY Radius

Units:
µm
Quantities Measured:
• cyst XY radius
• mean lumen XY radius
• mean nuclear XY radius
• standard deviation nuclear XY radius
Approach:
100

1. Calculate the image slice where the object has the largest area.
2. Calculate the center of the object on this slice.
3. Measure the distance between all boundary points (on this slice) and the center.
4. Take the mean.

B.6

Z Radius

Units:
µm
Quantities Measured:
• cyst Z radius
• mean lumen Z radius
• mean nuclear Z radius
• standard deviation nuclear Z radius
Approach:
1. Calculate the maximum z coordinate of the object.
2. Subtract the minimum z coordinate of the object. and the center.

B.7

Z:XY Radius

Units:
unitless
Quantities Measured:
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• cyst Z:XY radius
• mean lumen Z:XY radius
• mean nuclear Z:XY radius
• standard deviation nuclear Z:XY radius
Approach:
1. Divide the Z radius by the XY radius.

B.8

3D Radius

Units:
unitless
Quantities Measured:
• cyst 3D radius standard deviation
• cyst 3D radius coefficient of variation
Approach:
1. Calculate the image slice where the object has the largest area.
2. Calculate the center of the object on this slice.
3. Measure the distance between all boundary points (on this slice) and the center.
4. Take the standard deviation or coefficient of variation.
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B.9

External Cell Height

Units:
µm
Quantities Measured:
• external cell height
Approach:
1. For every cyst coordinate, calculate the distance to the nearest lumen coordinate.
2. Take the mean.

B.10

External Cell Width

Units:
µm
Quantities Measured:
• mean external cell width
• standard deviation external cell width
Approach:
1. Calculate the center of each nucleus.
2. For each nucleus, calculate the distance to the nearest nucleus center.

B.11

Major Axis

Units:
103

µm
Quantities Measured:
• cyst major axis
• mean lumen major axis
• mean nuclear major axis
• standard deviation nuclear major axis
Approach:
1. Calculate the image slice where the object has the largest area.
2. Use MATLAB’s regionprops function to calculate the major axis of the object on that slice.
3. Divide by 2.
4. Multiply by the size of the voxel in XY.

B.12

Minor Axis

Units:
µm
Quantities Measured:
• cyst minor axis
• mean lumen minor axis
• mean nuclear minor axis
• standard deviation nuclear minor axis
Approach:
104

1. Calculate the image slice where the object has the largest area.
2. Use MATLAB’s regionprops function to calculate the minor axis of the object on that slice.
3. Divide by 2.
4. Multiply by the size of the voxel in XY.

B.13

Major:Minor Axis

Units:
unitless
Quantities Measured:
• cyst major:minor axis
• mean lumen major:minor axis
• mean nuclear major:minor axis
• standard deviation nuclear major:minor axis
Approach:
1. Divide the major axis by the minor axis.

B.14

Solidity

Units:
unitless
Quantities Measured:
• cyst solidity
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• mean lumen solidity
• mean nuclear solidity
• standard deviation nuclear solidity
Approach:
1. Use MATLAB’s regionprops function to calculate the solidity of the 3D object.

B.15

Eccentricity

Units:
unitless
Quantities Measured:
• cyst eccentricity
• mean lumen eccentricity
• mean nuclear eccentricity
• standard deviation nuclear eccentricity
Approach:
1. Calculate the image slice where the object has the largest area.
2. Use MATLAB’s regionprops function to calculate the eccentricity of the object on that slice.

B.16

Number

Units:
unitless
Quantities Measured:
106

• number of lumens
• number of nuclei
• number of internal nuclei
• number of external nuclei
Approach:
1. Count the number of objects.

B.17

Density

Units:
1 / µm3
Quantities Measured:
• density of lumens
• density of nuclei
Approach:
1. Divide the number of objects by the cyst volume.
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